The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bandeira-Melo, C.
Right arrow Articles by Serhan, C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bandeira-Melo, C.
Right arrow Articles by Serhan, C. N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
The Journal of Immunology, 2000, 164: 2267-2271.
Copyright © 2000 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1

Christianne Bandeira-Melo*, Patricia T. Bozza2,*, Bruno L. Diaz*, Renato S. B. Cordeiro*, Peter J. Jose{dagger}, Marco A. Martins* and Charles N. Serhan{ddagger}

* Department of Physiology and Pharmacodynamics, Oswaldo Cruz Institute, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil; {dagger} Leucocyte Biology, Biomedical Sciences Division, Imperial College School of Medicine, London, United Kingdom; and {ddagger} Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, MA 02115

Tissue eosinophilia prevention represents one of the primary targets to new anti-allergic therapies. As lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are emerging as endogenous "stop signals" produced in distinct pathologies including some eosinophil-related pulmonary disorders, we evaluated the impact of in situ LXA4/ATL metabolically stable analogues on allergen-induced eosinophilic pleurisy in sensitized rats. LXA4/ATL analogues dramatically blocked allergic pleural eosinophil influx, while concurrently increasing circulating eosinophilia, inhibiting the earlier edema and neutrophilia associated with allergic reaction. The mechanisms underlying this LXA4/ATL-driven allergic eosinophilia blockade was independent of mast cell degranulation and involved LXA4/ATL inhibition of both IL-5 and eotaxin generation, as well as platelet activating factor action. These findings reveal LXA4/ATL as a novel class of endogenous anti-allergic mediators, capable of preventing local eosinophilia.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
I. Hecht, J. Rong, A. L. F. Sampaio, C. Hermesh, C. Rutledge, R. Shemesh, A. Toporik, M. Beiman, L. Dassa, H. Niv, et al.
A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 426 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S.-H. Wu, P.-Y. Liao, P.-L. Yin, Y.-M. Zhang, and L. Dong
Elevated Expressions of 15-Lipoxygenase and Lipoxin A4 in Children with Acute Poststreptococcal Glomerulonephritis
Am. J. Pathol., January 1, 2009; 174(1): 115 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Starosta, K. Pazdrak, I. Boldogh, T. Svider, and A. Kurosky
Lipoxin A4 Counterregulates GM-CSF Signaling in Eosinophilic Granulocytes
J. Immunol., December 15, 2008; 181(12): 8688 - 8699.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
F. Herb, T. Thye, S. Niemann, E. N.L. Browne, M. A. Chinbuah, J. Gyapong, I. Osei, E. Owusu-Dabo, O. Werz, S. Rusch-Gerdes, et al.
ALOX5 variants associated with susceptibility to human pulmonary tuberculosis
Hum. Mol. Genet., April 1, 2008; 17(7): 1052 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. D. Levy, N. W. Lukacs, A. A. Berlin, B. Schmidt, W. J. Guilford, C. N. Serhan, and J. F. Parkinson
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism
FASEB J, December 1, 2007; 21(14): 3877 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. Haworth and B. D. Levy
Endogenous lipid mediators in the resolution of airway inflammation
Eur. Respir. J., November 1, 2007; 30(5): 980 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Chiang, C. N. Serhan, S.-E. Dahlen, J. M. Drazen, D. W. P. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Pharmacol. Rev., September 1, 2006; 58(3): 463 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Rodgers, B. McMahon, D. Mitchell, D. Sadlier, and C. Godson
Lipoxin A4 Modifies Platelet-Derived Growth Factor-Induced Profibrotic Gene Expression in Human Renal Mesangial Cells
Am. J. Pathol., September 1, 2005; 167(3): 683 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
V. Nascimento-Silva, M. A. Arruda, C. Barja-Fidalgo, C. G. Villela, and I. M. Fierro
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells
Am J Physiol Cell Physiol, September 1, 2005; 289(3): C557 - C563.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Bandeira-Melo, A. G. C. Bonavita, B. L. Diaz, P. M. R. e Silva, V. F. Carvalho, P. J. Jose, R. J. Flower, M. Perretti, and M. A. Martins
A Novel Effect for Annexin 1-Derived Peptide Ac2-26: Reduction of Allergic Inflammation in the Rat
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1416 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. L. Bannenberg, J. Aliberti, S. Hong, A. Sher, and C. Serhan
Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis
J. Exp. Med., February 17, 2004; 199(4): 515 - 523.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. Y. Larbi, J. P. Dangerfield, F. J. Culley, D. Marshall, D. O. Haskard, P. J. Jose, T. J. Williams, and S. Nourshargh
P-selectin mediates IL-13-induced eosinophil transmigration but not eotaxin generation in vivo: a comparative study with IL-4-elicited responses
J. Leukoc. Biol., January 1, 2003; 73(1): 65 - 73.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. J. Schottelius, C. Giesen, K. Asadullah, I. M. Fierro, S. P. Colgan, J. Bauman, W. Guilford, H. D. Perez, and J. F. Parkinson
An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile
J. Immunol., December 15, 2002; 169(12): 7063 - 7070.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. Aliberti, C. Serhan, and A. Sher
Parasite-induced Lipoxin A4 Is an Endogenous Regulator of IL-12 Production and Immunopathology in Toxoplasma gondii Infection
J. Exp. Med., November 4, 2002; 196(9): 1253 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
L. Svensson, C. Dahlgren, and C. Wenneras
The chemoattractant Trp-Lys-Tyr-Met-Val-D-Met activates eosinophils through the formyl peptide receptor and one of its homologues, formyl peptide receptor-like 1
J. Leukoc. Biol., October 1, 2002; 72(4): 810 - 818.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Mitchell, G. Thomas, K. Harvey, D. Cottell, K. Reville, G. Berlasconi, N. A. Petasis, L. Erwig, A. J. Rees, J. Savill, et al.
Lipoxins, Aspirin-Triggered Epi-Lipoxins, Lipoxin Stable Analogues, and the Resolution of Inflammation: Stimulation of Macrophage Phagocytosis of Apoptotic Neutrophils In Vivo
J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2497 - 2507.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Penido, H. C. Castro-Faria-Neto, A. Vieira-de-Abreu, R. T. Figueiredo, A. Pelled, M. A. Martins, P. J. Jose, T. J. Williams, and P. T. Bozza
LPS Induces Eosinophil Migration via CCR3 Signaling Through a Mechanism Independent of RANTES and Eotaxin
Am. J. Respir. Cell Mol. Biol., December 1, 2001; 25(6): 707 - 716.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.